Iterum Therapeutics plc
DelistedCIK 1659323fmd_1WX2DY9T7FH9MEJV08YK68YVQ3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2025, 35 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 1 | 1 | 0 | 0 | 0 | – | – | – |
| Realized investment gains (losses) | – | – | 0 | 0 | – | – | – | – | – |
| Research and development | 10 | 25 | 69 | 91 | 21 | 11 | 18 | 40 | 10 |
| Total operating expenses | 13 | 30 | 77 | 102 | 32 | 25 | 30 | 47 | 19 |
| Operating income | (13) | (29) | (77) | (102) | (32) | (25) | (30) | (47) | (19) |
| Interest expense | – | – | – | – | – | – | 3 | 3 | 3 |
| Interest and investment income | – | – | – | – | – | – | 1 | 2 | 1 |
| Other non-operating income (expense) | 0 | 0 | (0) | (1) | (19) | (66) | (14) | 10 | (6) |
| Income before taxes | (13) | (29) | (77) | (103) | (51) | (91) | (44) | (38) | (25) |
| Income tax expense | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| Net income from continuing operations | (13) | (29) | (77) | (103) | (52) | (92) | (44) | (38) | (25) |
| Net income | (13) | (29) | (77) | (103) | (52) | (92) | (44) | (38) | (25) |
| Net income to common shareholders | (13) | (29) | (77) | (103) | (52) | (92) | (44) | (38) | (25) |